MX2019015320A - Antagonistas del receptor del factor liberador de corticotropina. - Google Patents
Antagonistas del receptor del factor liberador de corticotropina.Info
- Publication number
- MX2019015320A MX2019015320A MX2019015320A MX2019015320A MX2019015320A MX 2019015320 A MX2019015320 A MX 2019015320A MX 2019015320 A MX2019015320 A MX 2019015320A MX 2019015320 A MX2019015320 A MX 2019015320A MX 2019015320 A MX2019015320 A MX 2019015320A
- Authority
- MX
- Mexico
- Prior art keywords
- receptor antagonists
- factor receptor
- release factor
- corticotropin release
- corticotropin
- Prior art date
Links
- 102400000739 Corticotropin Human genes 0.000 title 1
- 101800000414 Corticotropin Proteins 0.000 title 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 title 1
- 229960000258 corticotropin Drugs 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 208000005676 Adrenogenital syndrome Diseases 0.000 abstract 2
- 208000008448 Congenital adrenal hyperplasia Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762545406P | 2017-08-14 | 2017-08-14 | |
| PCT/US2018/046760 WO2019036503A1 (en) | 2017-08-14 | 2018-08-14 | CORTICOTROPIN RELEASE FACTOR RECEPTOR ANTAGONISTS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019015320A true MX2019015320A (es) | 2020-07-20 |
Family
ID=65362494
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019015320A MX2019015320A (es) | 2017-08-14 | 2018-08-14 | Antagonistas del receptor del factor liberador de corticotropina. |
| MX2023000501A MX2023000501A (es) | 2017-08-14 | 2019-12-16 | Antagonistas del receptor del factor liberador de corticotropina. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023000501A MX2023000501A (es) | 2017-08-14 | 2019-12-16 | Antagonistas del receptor del factor liberador de corticotropina. |
Country Status (11)
| Country | Link |
|---|---|
| US (9) | US20210361664A1 (enExample) |
| EP (1) | EP3628005A4 (enExample) |
| JP (3) | JP7398963B2 (enExample) |
| KR (2) | KR20250022913A (enExample) |
| CN (2) | CN110996943A (enExample) |
| AU (2) | AU2018317398A1 (enExample) |
| BR (1) | BR112020002967A2 (enExample) |
| CA (1) | CA3064464A1 (enExample) |
| EA (1) | EA202090450A1 (enExample) |
| MX (2) | MX2019015320A (enExample) |
| WO (1) | WO2019036503A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210064407A (ko) | 2014-01-21 | 2021-06-02 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 선천성 부신 과형성 치료를 위한 ｃｒｆ1 수용체 길항제 |
| BR112020002967A2 (pt) | 2017-08-14 | 2020-08-11 | Spruce Biosciences, Inc. | antagonistas de receptor de fator de liberação de corticotropina |
| MX2020011344A (es) * | 2018-04-27 | 2021-02-09 | Spruce Biosciences Inc | Métodos para tratar tumores en reposo suprarrenales testiculares y de ovarios. |
| PL3984523T3 (pl) * | 2018-12-07 | 2026-02-02 | Neurocrine Biosciences, Inc. | Antagonista receptora crf1, jego formulacje farmaceutyczne i postacie stałe do leczenia wrodzonego przerostu nadnerczy |
| KR20220052927A (ko) | 2019-07-19 | 2022-04-28 | 스프루스 바이오사이언시스 인코포레이티드 | 선천성 부신 증식증의 치료 방법 |
| US12383536B2 (en) | 2019-09-27 | 2025-08-12 | Neurocrine Biosciences, Inc. | CRF receptor antagonists and methods of use |
| ES3039926T3 (en) | 2019-12-04 | 2025-10-27 | Neurocrine Biosciences Inc | Crf receptor antagonists and methods of use |
| JP2023537598A (ja) | 2020-08-12 | 2023-09-04 | スプルース バイオサイエンシーズ，インク． | 多嚢胞性卵巣症候群を処置するための方法および組成物 |
| US20240024330A1 (en) * | 2020-08-26 | 2024-01-25 | Neurocrine Biosciences, Inc. | Crf receptor antagonists and methods of use |
| US11708372B2 (en) | 2021-11-19 | 2023-07-25 | Spruce Biosciences, Inc. | Crystalline composition of tildacerfont and methods of use and preparation thereof |
| WO2025188842A1 (en) * | 2024-03-08 | 2025-09-12 | Spruce Biosciences, Inc. | Amorphous solid dispersion of tildacerfont formulations |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9307646A (pt) | 1992-12-17 | 1999-05-25 | Pfizer | Pirrolopirimidinas como antagonistas de crf |
| ES2168237T3 (es) | 1996-02-07 | 2007-04-01 | Neurocrine Biosciences, Inc. | Pirazolopirimidinas como antagonistas de receptores de crf. |
| CZ299451B6 (cs) | 1996-07-24 | 2008-07-30 | Bristol-Myers Squibb Pharma Company | [1,5-a]-Pyrazolo-1,3,5- triaziny jejich použití afarmaceutické kompozice na jejich bázi |
| AU747708B2 (en) | 1996-07-24 | 2002-05-23 | Du Pont Pharmaceuticals Company | Azolo triazines and pyrimidines |
| PL332040A1 (en) | 1996-08-28 | 1999-08-16 | Pfizer | Substitution 6,5-heterobicyclic derivatives |
| IL137019A (en) | 1998-01-28 | 2010-11-30 | Du Pont Pharm Co | 2,7 - dimethyl - 4 - (substituted amino) - 8 - arylpyrazolo [1,5-a] triazine derivatives and pharmaceutical compositions containing them |
| IL137019A0 (en) | 1998-01-28 | 2001-06-14 | Du Pont Pharm Co | Azolo triazines and pyrimidines |
| EP1040831A3 (en) | 1999-04-02 | 2003-05-02 | Pfizer Products Inc. | Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death |
| AU4203500A (en) | 1999-04-06 | 2000-10-23 | Du Pont Pharmaceuticals Company | Pyrazolopyrimidines as crf antagonists |
| YU23602A (sh) | 1999-09-30 | 2004-09-03 | Neurogen Corporation | Amino supstituisani pirazolo /1,5/a/-1,5-pirimidini i pirazolo /1,5-a/-1,3,5-triazini |
| HRP20010582A2 (en) | 1999-12-08 | 2002-08-31 | Pharmacia Corp | Valdecoxib compositions |
| ES2282401T3 (es) | 2001-03-13 | 2007-10-16 | Bristol-Myers Squibb Pharma Company | 4-(2-butilamino)-2,7-dimetil-8-(2-metil-6-metoxipirid-3-il) pirazolo - 1,5-a-1,3,5-triazina, sus enantiomeros y sales farmaceuticamente aceptables como ligandos del receptor del factor liberador de croticotropina. |
| WO2005020910A2 (en) | 2003-08-27 | 2005-03-10 | Pharmacia Corporation | Cyclooxygenase-2 selective inhibitor and corticotropin releasing factor antagonist compositions for treating ischemic mediated cns disorders or injuries |
| US8304431B2 (en) | 2003-12-02 | 2012-11-06 | Pharmaneuroboost N.V. | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| JP4926720B2 (ja) | 2003-12-22 | 2012-05-09 | スミスクライン ビーチャム （コーク） リミテッド | Ｃｒｆ受容体アンタゴニストおよびそれらに関連する方法 |
| JP2008503444A (ja) | 2004-02-13 | 2008-02-07 | エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド | Ｃｒｆ受容体アンタゴニスト、その調製法、その医薬組成物およびその使用 |
| CA2556160A1 (en) | 2004-02-13 | 2005-09-01 | Pfizer Products Inc. | Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists |
| US20060078623A1 (en) * | 2004-08-13 | 2006-04-13 | Emisphere Technologies, Inc. | Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent |
| CN101142217B (zh) | 2005-03-21 | 2010-12-08 | 伊莱利利公司 | 咪唑并哒嗪化合物 |
| CN101516835A (zh) | 2006-07-19 | 2009-08-26 | 俄亥俄州立大学研究基金会 | 选择性雄激素受体调节剂、它们的类似物和衍生物以及它们的用途 |
| MX2009003098A (es) | 2006-09-20 | 2009-04-01 | Lilly Co Eli | Compuestos de tiofen pirazolopirimidina. |
| KR101088239B1 (ko) | 2006-09-20 | 2011-11-30 | 일라이 릴리 앤드 캄파니 | Ｃｒｆ１ 수용체 길항제로서의 티아졸 피라졸로피리미딘 |
| US8952207B2 (en) | 2007-09-11 | 2015-02-10 | The University Of Houston System | Copper-catalyzed C—H bond arylation |
| US8318813B2 (en) | 2007-09-13 | 2012-11-27 | Lcs Group, Llc | Method of treating binge eating disorder |
| TWI432435B (zh) | 2008-10-02 | 2014-04-01 | Lilly Co Eli | 作為合成中間物之噻唑基－吡唑并嘧啶化合物及相關合成方法 |
| EP4718073A3 (en) * | 2008-12-24 | 2026-07-29 | Quest Diagnostics Investments LLC | Mass spectrometry assay for congenital adrenal hyperplasia |
| US20110160168A1 (en) * | 2009-12-31 | 2011-06-30 | Differential Drug Development Associates, Llc | Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols |
| US9750568B2 (en) | 2012-03-08 | 2017-09-05 | Medtronic Ardian Luxembourg S.A.R.L. | Ovarian neuromodulation and associated systems and methods |
| JP2015516979A (ja) | 2012-04-23 | 2015-06-18 | ホルスボールマッシュマイヤー ニューロケミー ゲーエムベーハーＨｏｌｓｂｏｅｒｍａｓｃｈｍｅｙｅｒ Ｎｅｕｒｏｃｈｅｍｉｅ Ｇｍｂｈ | Ｃｒｈ過剰活性を有する患者の治療に用いるためのｃｒｈｒ１アンタゴニスト |
| KR20210064407A (ko) * | 2014-01-21 | 2021-06-02 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 선천성 부신 과형성 치료를 위한 ｃｒｆ1 수용체 길항제 |
| ES2964948T3 (es) | 2015-03-31 | 2024-04-10 | May Health Us Inc | Métodos y sistemas para la manipulación de tejidos ováricos |
| TWI803504B (zh) | 2017-08-14 | 2023-06-01 | 美商雲杉生物科技股份有限公司 | 促皮質素釋放因子受體拮抗劑 |
| BR112020002967A2 (pt) | 2017-08-14 | 2020-08-11 | Spruce Biosciences, Inc. | antagonistas de receptor de fator de liberação de corticotropina |
| MX2020011344A (es) | 2018-04-27 | 2021-02-09 | Spruce Biosciences Inc | Métodos para tratar tumores en reposo suprarrenales testiculares y de ovarios. |
| PL3984523T3 (pl) | 2018-12-07 | 2026-02-02 | Neurocrine Biosciences, Inc. | Antagonista receptora crf1, jego formulacje farmaceutyczne i postacie stałe do leczenia wrodzonego przerostu nadnerczy |
| US20200255436A1 (en) | 2019-02-12 | 2020-08-13 | Spruce Biosciences, Inc. | Corticotropin releasing factor receptor antagonists |
| KR20220052927A (ko) | 2019-07-19 | 2022-04-28 | 스프루스 바이오사이언시스 인코포레이티드 | 선천성 부신 증식증의 치료 방법 |
| JP2023537598A (ja) | 2020-08-12 | 2023-09-04 | スプルース バイオサイエンシーズ，インク． | 多嚢胞性卵巣症候群を処置するための方法および組成物 |
| US11708372B2 (en) | 2021-11-19 | 2023-07-25 | Spruce Biosciences, Inc. | Crystalline composition of tildacerfont and methods of use and preparation thereof |
| EP4402142A4 (en) | 2021-11-19 | 2025-07-23 | Spruce Biosciences Inc | CRYSTALLINE COMPOSITION OF TILDACERFONT AND ITS METHODS OF USE AND PREPARATION |
-
2018
- 2018-08-14 BR BR112020002967-0A patent/BR112020002967A2/pt not_active Application Discontinuation
- 2018-08-14 KR KR1020257004457A patent/KR20250022913A/ko active Pending
- 2018-08-14 AU AU2018317398A patent/AU2018317398A1/en not_active Abandoned
- 2018-08-14 CN CN201880038569.3A patent/CN110996943A/zh active Pending
- 2018-08-14 CN CN202410709847.0A patent/CN118845788A/zh active Pending
- 2018-08-14 US US16/639,541 patent/US20210361664A1/en not_active Abandoned
- 2018-08-14 JP JP2019572817A patent/JP7398963B2/ja active Active
- 2018-08-14 WO PCT/US2018/046760 patent/WO2019036503A1/en not_active Ceased
- 2018-08-14 MX MX2019015320A patent/MX2019015320A/es unknown
- 2018-08-14 CA CA3064464A patent/CA3064464A1/en active Pending
- 2018-08-14 EP EP18846689.0A patent/EP3628005A4/en active Pending
- 2018-08-14 KR KR1020207004095A patent/KR20200040761A/ko not_active Ceased
- 2018-08-14 EA EA202090450A patent/EA202090450A1/ru unknown
-
2019
- 2019-04-18 US US16/388,620 patent/US10849908B2/en active Active
- 2019-12-16 MX MX2023000501A patent/MX2023000501A/es unknown
-
2020
- 2020-10-05 US US17/063,592 patent/US11344557B2/en active Active
- 2020-10-22 US US17/078,054 patent/US11007201B2/en active Active
-
2021
- 2021-06-25 US US17/359,411 patent/US11351177B2/en active Active
- 2021-06-25 US US17/359,414 patent/US11311549B2/en active Active
-
2022
- 2022-01-27 US US17/586,228 patent/US20220143037A1/en not_active Abandoned
- 2022-12-09 US US18/078,649 patent/US20230321112A1/en not_active Abandoned
-
2023
- 2023-01-13 AU AU2023200189A patent/AU2023200189B2/en active Active
- 2023-04-26 US US18/307,718 patent/US12115166B2/en active Active
- 2023-09-08 JP JP2023146415A patent/JP7573080B2/ja active Active
-
2024
- 2024-10-11 JP JP2024179270A patent/JP2025020148A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023000501A (es) | Antagonistas del receptor del factor liberador de corticotropina. | |
| MX2022015858A (es) | Antagonistas del receptor del factor liberador de corticotropina. | |
| CO2019012353A2 (es) | Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1 | |
| DOP2017000199A (es) | Receptores de antígeno quiméricos ant- dll3 y métodos de uso | |
| CL2019000941A1 (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret. | |
| DOP2022000077A (es) | Aminas bicíclicas como inhibidoras de la cdk2 | |
| CL2017001289A1 (es) | Compuestos bicíclicos fusionados, sus composiciones y su uso para el tratamiento de enfermedades relacionadas con la modulación del receptor x farnesoide (fxr). | |
| DK3230298T3 (da) | 3-substituerede 5-amino-6H-thiazolo[4,5-d]pyrimidin-2,7-dion forbindelser til behandling og forebyggelse af virusinfektion | |
| CL2016001895A1 (es) | Compuestos | |
| SI3984523T1 (sl) | Antagonist receptorja crf1, njegove farmacevtske formulacije in trdne oblike za zdravljenje kongenitalne adrenalne hiperplazije | |
| WO2019123294A3 (en) | Pyrazolo piperidine and pyrazolo pyrimidine derivatives for the treatment of neuropsychiatric systemic lupus erythematosus | |
| EA201591255A1 (ru) | ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-РОДСТВЕННЫХ КИНАЗ (JAK) | |
| EA201790995A1 (ru) | ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ | |
| CL2016001840A1 (es) | Compuestos derivados de pirimidinas fusionadas como inhibidores del complejo p97; composicion farmaceutica y uso en el tratamiento del cancer. | |
| CO2017007121A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| MX2022002954A (es) | Anticuerpos anti-htra1 y metodos de uso de los mismos. | |
| CL2016002008A1 (es) | Proceso para la elaboración de derivados de pirimidin sulfamida. | |
| MX373652B (es) | Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa. | |
| PH12017500161A1 (en) | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | |
| MX374555B (es) | Derivados de pirimidina como inhibidores de tirosina cinasa de bruton (btk) y usos de los mismos. | |
| WO2018067520A3 (en) | Therapeutic agents and methods: | |
| PH12017500170A1 (en) | 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglur2 receptors | |
| MX2022011972A (es) | Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas. | |
| WO2018094106A3 (en) | ALLOSTERIC ANTAGONISTS OF GPRC6a AND THEIR USE IN MITIGATING PROTEINOPATHIES | |
| JO3601B1 (ar) | مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2 |